Gain Therapeutics (GANX) Exchange Rate Effect (2020 - 2026)
Gain Therapeutics (GANX) posted Exchange Rate Effect of -$141631.0 for Q2 2026, down 675.99% on a QoQ basis from $24589.0 in Q1 2026, and down 154.46% year-over-year from $260070.0 in Q2 2025.
Powered by 
Analysis
Gain Therapeutics (GANX) Exchange Rate Effect (2020 - 2026) Analysis & Trends
Gain Therapeutics has reported Exchange Rate Effect for 7 years, with the latest figure at -$141631.0 in Q2 2026.
- On a quarterly basis, Exchange Rate Effect fell 154.46% year-over-year to -$141631.0 in Q2 2026; TTM through Jun 2026 was -$12615.0, a 104.64% decrease from a year earlier, with the FY2025 full-year figure at $474032.0, up 189.92% from the prior year.
- Exchange Rate Effect was -$141631.0 for Q2 2026 at Gain Therapeutics, down from $24589.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $483249.0 in Q4 2023, with the low at -$480592.0 in Q4 2024.
- Average Exchange Rate Effect over 5 years is $16357.2, with a median of $18855.5 recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect plunged 1251.69% in 2024, then surged 1881.94% in 2025.
- Over 5 years, Exchange Rate Effect stood at $226051.0 in 2022, then jumped by 113.78% to $483249.0 in 2023, then tumbled by 199.45% to -$480592.0 in 2024, then surged by 120.34% to $97760.0 in 2025, then tumbled by 244.88% to -$141631.0 in 2026.
- The last three Exchange Rate Effect figures came in at -$141631.0 (Q2 2026), $24589.0 (Q1 2026), and $97760.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 315,000.00 |
| 10 | Gain Therapeutics | 73.54 Mn | 73.54 Mn | - | -141,631.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -141,631.00 |
| Mar 31, 2026 | 24,589.00 |
| Dec 31, 2025 | 97,760.00 |
| Sep 30, 2025 | 6,667.00 |
| Jun 30, 2025 | 260,070.00 |
| Mar 31, 2025 | 109,535.00 |
| Dec 31, 2024 | -480,592.00 |
| Sep 30, 2024 | 382,805.00 |
| Jun 30, 2024 | 13,122.00 |
| Mar 31, 2024 | -442,503.00 |
| Dec 31, 2023 | 483,249.00 |
| Sep 30, 2023 | -144,578.00 |
| Jun 30, 2023 | 111,311.00 |
| Mar 31, 2023 | 38,422.00 |
| Dec 31, 2022 | 226,051.00 |
| Sep 30, 2022 | -105,973.00 |
| Jun 30, 2022 | -94,558.00 |
| Mar 31, 2022 | -49,317.00 |
| Dec 31, 2021 | 64,508.00 |
| Sep 30, 2021 | 34,451.00 |